Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]
News [7787]
Articles [63]
Editorials [9]
Conferences [208]
elearning [49]
Rituximab versus idelalisib in refractory CLL
Prof John Gribben - Queen Mary University London, London, UK; Prof Peter...
Rituximab versus idelalisib in refractory CLL ( Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK )
9 May 2014
New agents extend progression-free survival in double refractory myeloma
Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta...
New agents extend progression-free survival in double refractory myeloma ( Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA )
8 May 2014
Aspirin analogues developed for anti-cancer effects on leukaemia
Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK
Aspirin analogues developed for anti-cancer effects on leukaemia ( Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK )
8 May 2014
Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic...
Dr Valentin Goede - University of Cologne, Cologne, Germany
Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients ( Dr Valentin Goede - University of Cologne, Cologne, Germany )
8 May 2014
WIN Symposium 2014: Breakthrough biomarker investigations and combination...
Dr John Mendelsohn, Dr Razelle Kurzrock, Dr Mace Rothenberg
WIN Symposium 2014: Breakthrough biomarker investigations and combination therapies ( Dr John Mendelsohn, Dr Razelle Kurzrock, Dr Mace Rothenberg )
6 May 2014
Work and history of the Kidney Cancer Association
Carrie Konosky - Vice President of Development & Public Affairs, Kidney Cancer...
Work and history of the Kidney Cancer Association ( Carrie Konosky - Vice President of Development & Public Affairs, Kidney Cancer Association, Chicago, USA )
6 May 2014
Kidney cancer treatment ten years from now
Prof Martin Gore - The Royal Marsden Hospital, London, UK
Kidney cancer treatment ten years from now ( Prof Martin Gore - The Royal Marsden Hospital, London, UK )
6 May 2014
New drug OTX15 shows early promise in fighting acute myeloid leukaemia
Dr Esteban Cvitkovic - Oncoethix, Lausanne, Switzerland
New drug OTX15 shows early promise in fighting acute myeloid leukaemia ( Dr Esteban Cvitkovic - Oncoethix, Lausanne, Switzerland )
5 May 2014
Personalisation of leukaemia treatment using genome sequencing
Dr Giovanni Martinelli - University of Bologna, Bologna, Italy
Personalisation of leukaemia treatment using genome sequencing ( Dr Giovanni Martinelli - University of Bologna, Bologna, Italy )
5 May 2014
History and ongoing work of AORTIC
Dr James Holland - Mount Sinai Hospital, New York, USA
History and ongoing work of AORTIC ( Dr James Holland - Mount Sinai Hospital, New York, USA )
5 May 2014
AORTIC and the benefits of coordination between different US NCI-designated...
Dr Lisa Stevens - National Cancer Institute, Bethesda, USA
AORTIC and the benefits of coordination between different US NCI-designated cancer centres in Kenya ( Dr Lisa Stevens - National Cancer Institute, Bethesda, USA )
5 May 2014
Subset of breast cancer patients found to benefit from neratinib in latest trial
Dr John W. Park - University of California San Francisco, San Francisco, USA
Subset of breast cancer patients found to benefit from neratinib in latest trial ( Dr John W. Park - University of California San Francisco, San Francisco, USA )
1 May 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation